SEC For																		
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					d pursuant	CHANGE to Section 16(a on 30(h) of the	i) of the S	ecuriti	es Exchan	iqe Ac	ct of 193		HIP	Estima	Number ated ave per res	erage burde	3235-0287 n 0.5	
1. Name and Address of Reporting Person <sup>*</sup> <u>Mahatme Sandesh</u>					2. Issuer Name and Ticker or Trading Symbol <u>CRISPR Therapeutics AG</u> [ CRSP ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)					3. Date of Earliest Transaction (Month/Day/Year) 05/30/2024								Officer below)	(give title	Other (sp below)		specify	
C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET					Line)							loint/Group Filing (Check Applicable iled by One Reporting Person						
(Street) BOSTON MA 02127				Form file Person									ed by More than One Reporting					
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication         Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - Nor	n-Deriv	ative Se	curities Ac	quired	, Disj	oosed o	of, or	r Bene	ficially	y Owned					
Date				Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Yea	Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	mount (/		Price	Transact (Instr. 3 a	ion(s)			(	
		-				urities Acq s, warrants							Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date, T	ransaction ode (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date E Expiratio (Month/I	on Date		of Se Unde Deriv	tle and A ecurities erlying vative So vative So tr. 3 and	ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	

Explanation of Responses:
1. This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders.

05/30/2024

Stock Option (Right to Buy)

\$54.06

/s/ AJ Silver, attorney-in-fact	05/31/2024
** Signature of Reporting Person	Date

Amount or Number

Shares

13,000

\$<mark>0</mark>

13,000

D

of

Title

Common Shares

Expiration Date

05/30/2034

Date

(D)

Exercisable

(1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

۷

(A)

13,000

Code

Α

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.